Jeffrey Schatz1, Alyssa Schlenz, Laura Reinman, Kelsey Smith, Carla W Roberts. 1. *Department of Psychology, University of South Carolina, Columbia, SC; †Department of Pediatrics, Medical University of South Carolina, Charleston, SC; ‡Department of Pediatrics, University of South Carolina, Columbia, SC.
Abstract
OBJECTIVE: Studies of early child development in sickle cell disease (SCD) have found modest associations between disease-related risks and developmental status in infants and toddlers, but such associations are evident by early elementary school. We screened 4-year-old children with SCD using 2 screening strategies to assess if biomedical risk factors for neurologic disease are related to developmental screening outcomes at this intermediate age. METHODS: Seventy-seven 4-year-old children with SCD (M = 4.5 yrs, SD = 0.3 yrs) completed developmental screenings at routine hematology visits using child testing (Fluharty Preschool Speech and Language Screenings Test, 2nd edition) and parent-report (Ages and Stages Questionnaire, 2nd edition) procedures. Genotype and other biomedical variables were coded from medical records. RESULTS: Children with higher-risk SCD genotypes (n = 52) showed lower performance than children with lower-risk genotypes (n = 25) on a measure related to neurologic disease risk in older children (syntactic processing); genotype risk was also related to rates of positive screenings on parent-reported developmental milestones (52% positive screenings in high-risk genotypes vs 12% in low-risk genotypes). Screening outcomes were also related to transcranial Doppler ultrasound findings assessing cerebral blood flow. CONCLUSION: Developmental screening at age 4 may be a useful target age for identifying preschoolers with sickle cell-related neurodevelopmental concerns. Parent report of developmental milestones and behavioral testing each may have a role in screening for children in need of follow-up services to address potential neurodevelopmental effects from SCD.
OBJECTIVE: Studies of early child development in sickle cell disease (SCD) have found modest associations between disease-related risks and developmental status in infants and toddlers, but such associations are evident by early elementary school. We screened 4-year-old children with SCD using 2 screening strategies to assess if biomedical risk factors for neurologic disease are related to developmental screening outcomes at this intermediate age. METHODS: Seventy-seven 4-year-old children with SCD (M = 4.5 yrs, SD = 0.3 yrs) completed developmental screenings at routine hematology visits using child testing (Fluharty Preschool Speech and Language Screenings Test, 2nd edition) and parent-report (Ages and Stages Questionnaire, 2nd edition) procedures. Genotype and other biomedical variables were coded from medical records. RESULTS:Children with higher-risk SCD genotypes (n = 52) showed lower performance than children with lower-risk genotypes (n = 25) on a measure related to neurologic disease risk in older children (syntactic processing); genotype risk was also related to rates of positive screenings on parent-reported developmental milestones (52% positive screenings in high-risk genotypes vs 12% in low-risk genotypes). Screening outcomes were also related to transcranial Doppler ultrasound findings assessing cerebral blood flow. CONCLUSION: Developmental screening at age 4 may be a useful target age for identifying preschoolers with sickle cell-related neurodevelopmental concerns. Parent report of developmental milestones and behavioral testing each may have a role in screening for children in need of follow-up services to address potential neurodevelopmental effects from SCD.
Authors: Leslie D Berkelhammer; Adrienne L Williamson; Stacy D Sanford; Courtney L Dirksen; William G Sharp; Allison S Margulies; Rebecca A Prengler Journal: Child Neuropsychol Date: 2007-03 Impact factor: 2.500
Authors: F Daniel Armstrong; T David Elkin; R Clark Brown; Penny Glass; Sohail Rana; James F Casella; Ram V Kalpatthi; Steven Pavlakis; Zhibao Mi; Winfred C Wang Journal: Pediatrics Date: 2013-01-06 Impact factor: 7.124
Authors: Banu Aygun; Jennifer Parker; Molly B Freeman; Alexis L Stephens; Matthew P Smeltzer; Song Wu; Jane S Hankins; Winfred C Wang Journal: Pediatr Blood Cancer Date: 2010-11-11 Impact factor: 3.167
Authors: R Grant Steen; X Joan Hu; Vanessa E Elliott; Mark A Miles; Shalita Jones; Winfred C Wang Journal: J Child Neurol Date: 2002-02 Impact factor: 1.987
Authors: Jeffrey Schatz; Catherine B McClellan; Eve S Puffer; Kenia Johnson; Carla W Roberts Journal: J Child Neurol Date: 2007-12-26 Impact factor: 1.987
Authors: Eboni I Lance; Alicia D Cannon; Bruce K Shapiro; Li-Ching Lee; Michael V Johnston; James F Casella Journal: J Dev Behav Pediatr Date: 2021-08-01 Impact factor: 2.988